Skip to main content
. Author manuscript; available in PMC: 2023 Oct 23.
Published in final edited form as: Cell Rep. 2023 Jan 25;42(2):112040. doi: 10.1016/j.celrep.2023.112040

Fig. 2. JAML expression on TRM cells is associated with patient survival.

Fig. 2.

A, Whole-slide multiplexed immunohistochemistry analysis of selected markers from a treatment-naïve patient with NSCLC. B, Whole-slide multiplexed immunohistochemistry analysis depicting the percentage of JAML-expressing CD8+ TRM (CD8+CD103+) and CD8+ non-TRM (CD8+CD103−) cells in the cohort of HNSCC patients. C,D, Survival curves of a HNSCC cohort (n=194) stratified into TRMhi and TRMlo (C), JAMLhi and JAMLlo TRM cells (D). All data are mean +/− S.E.M. Significance for comparisons was computed using two-tailed Wilcoxon matched-pairs signed rank test (B) or Mantel-Cox test (C,D), P = 0.1234; *P = 0.0332; **P = 0.0021; ***P = 0.0002; and ****P < 0.0001.